all

Nov. 10, 2018

CHICAGO ‒ The REDUCE-IT cardiovascular outcomes trial results, announced today at the American Heart Association Scientific Sessions in Chicago, met its primary composite endpoint and revealed a reduction in major adverse cardiovascular events (MACE) of 25%.

Download the manuscript online now.

Nov. 10, 2018

NLA among 12 organizations to co-author, endorse key document for reducing risk of atherosclerotic cardiovascular disease